Breast Cancer Diagnostic Market Analysis 2026

CURRENT SCENARIO OF THE BREAST CANCER DIAGNOSTICS MARKET

Key factors driving the Breast Cancer diagnostics Market

• The rising prevalence of breast cancer coupled with the rise in the emergence of new technologies in early screening and diagnosis is expected to drive the global breast cancer diagnostic market growth

The incidence of breast cancer is proliferating. As per the report presented by the World Health Organization (WHO), around 2.3 million women were affected due to breast cancer across the world in the year 2020 with 6,85,000 fatalities. 

In 2023, an estimated 297,790 new cases of invasive breast cancer are expected to be diagnosed in U.S. women, along with 55,720 new cases of DCIS.
(Source: https://www.breastcancer.org/facts-statistics)

Globally, breast cancer has been identified by the WHO as the most common type of cancer, with new cases surpassing 2.3 million in 2021. Hence, the increasing prevalence of breast cancer cases is booming the global breast cancer diagnostic market over the forecast period. 

Furthermore, technological advancements in imaging are creating improvements and opportunities in early detection and screening of the disease. One of the advanced technologies is 3-D mammography which is also known as tomosynthesis. This test takes images from various angles of the breast and develops them into a 3D shape.

For instance, on July 10th, 2019, Arizona-based SimonMed Imaging announced its implementation of the first U.S. Food and Drug Administration (FDA)-cleared artificial intelligence (AI) program for significantly enhancing early breast cancer detection for 3-D mammography. The AI program, called ProFound AI for digital breast tomosynthesis (DBT), was developed by iCAD Inc.
(Source:https://www.itnonline.com/content/simonmed-imaging-implements-profound-ai-3-d-tomosynthesis)

• Growing Aging Population to drive the market 

Aging is one of the greatest risk factors for breast cancer. With age, the immune system is affected. This increases susceptibility to various diseases.

According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age.
(Source:https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html)

Breast cancer diagnosis is relatively rare in younger women; only about one out of eight invasive breast cancers are diagnosed in women younger than 45, whereas about two out of three invasive breast cancers are found in women 55 or older.
(Source: https://www.breastcancer.org/facts-statistics)

Therefore, improved healthcare services are needed for the elderly population, particularly for the treatment and management of chronic illnesses like breast cancer. 

Breast cancer is the most frequent cancer among women, and in developing nations, where the majority of cases are detected at later stages, its prevalence is significantly rising. 

About 50% of cases and 58% of deaths from breast cancer occur in poor nations, despite the fact that the disease is thought to be more common in developed economies. 

Over the course of the projection period, this is anticipated to increase the need for breast cancer diagnostics in developing economies.

Factors Affecting the growth of the market

• Costly follow-ups for diagnosis, limited availability coupled with the stringent regulatory framework are likely to hamper the market growth

Global demand for breast cancer screening and diagnostic techniques is being hampered by a number of problems, including the high cost of follow-ups for diagnosis, scarcity of these services, and strict regulations. 
For instance, mammography costs around $200 and approx. 50% of women are poorly diagnosed. 

Because diagnostic imaging equipment is expensive, there is limited access to current cancer screening procedures in Eastern Europe, Asia, and Africa. 
The expense of setting up imaging centers and breast cancer diagnostic equipment, as well as the negative consequences of radiation, could impede the market's expansion. 

The market for breast screening and diagnostics is challenged by high percentages of false-positive cancer diagnosis results and indeterminate mammograms that need MRI, 3D mammography, and biopsies as follow-up procedures.

Opportunities

• Growing demand for technologically advanced products is expected to drive the global breast cancer screening and diagnostic techniques market growth

The primary growth element during the projected time is probably going to be the increasing need for technologically sophisticated items that can improve accuracy, speed, and cost-effectiveness. One example is the advent of Direct-To-Consumer (DTC) testing in the diagnoses of cancer. 

For instance, In April 2019, Hologic, Inc. launched the Trident® HD specimen radiography system, a next-generation solution that delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.

(Source: https://investors.hologic.com/press-releases/press-release-details/2019/Hologic-Launches-Trident-HD-Specimen-Radiography-System-in-United-States-Canada-and-Europe/default.aspx)

Breast cancer diagnoses have been completely transformed by advances in less invasive procedures. Methods like ultrasound-guided biopsies and stereotactic biopsies enable accurate tissue sample without the need for surgery. These techniques can also be applied to image-guided tumor ablation, which minimizes harm to healthy tissues while killing cancer cells. 

The increased demand for instruments for cancer diagnosis due to technology improvements is occurring on a global scale. The development of novel flow cytometry reagents for drug discovery & diagnosis, the introduction of cutting-edge miniaturized devices for portability & precision, and support from regulatory bodies like the FDA for the development of mass cytometry and cancer biomarkers are all factors driving the market growth.  

Moreover, initiatives to develop novel imaging solutions for more accurate cancer diagnosis are fueling market growth, such as the collaboration between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center to develop radiopharmaceutical products.

Also,  In April 2023, Myriad Genetics and SimonMed collaborated on a genetic cancer risk program, combining their expertise in genetics & medical imaging. This partnership aims to provide comprehensive risk assessment and personalized screening strategies for individuals at high risk of developing hereditary cancers.
(Source:https://investor.myriad.com/news-releases/news-release-detail/?newsItemId=23906)

How did COVID–19 Impact the Breast Cancer Diagnostics Market?

The market for breast cancer diagnostics has been severely disrupted by the COVID-19 pandemic, which has caused interruptions in the screening, diagnosis, and treatment processes. The pre-cancer, breast screening, and handling of bad test findings are among the elective healthcare services that have been severely disrupted by the COVID-19 pandemic. This is because pre-existing health disparities are being made worse by the rising incidence of breast cancer cases. In actuality, major industry participants are making a variety of decisions regarding R&D to generate new items and strategic alliances to enhance technology and test outcomes pertaining to the market.

• Routine breast cancer screenings and diagnostic procedures were delayed as a result of lockdown measures and overburdened healthcare institutions. The outcome of treatment and survival rates may be impacted if breast cancer is discovered later due to this delay in detection.

• Decreased Patient Visits: Patients were less likely to seek prompt medical attention for breast cancer signs because of their fear of contracting the virus and limitations on non-essential healthcare services. Delays in diagnosis and treatment commencement were further compounded by this decline in patient visits.

• Change in Healthcare Priorities: The management of COVID-19 patients took up more staff time and resources in the healthcare system, which left less time and money for the diagnosis and treatment of breast cancer. Accessing prompt and thorough breast cancer treatment has become more difficult as a result of the reorganization of healthcare systems.

• Impact on Research and Development: Due to limitations on laboratory access, participant recruitment, and funding, clinical trials and research activities pertaining to breast cancer diagnostics may have been postponed or disturbed. These setbacks may make it more difficult to develop novel breast cancer treatments and diagnostic tools.

• Telemedicine Adoption: In an effort to lessen the pandemic's effects on breast cancer treatment, medical professionals are using telemedicine and virtual consultations more frequently for patient assessment and follow-up. Even if telemedicine is safe and convenient during the pandemic, further research is needed to see how well it works for diagnosing and tracking breast cancer.

Post-pandemic - In spite of the pandemic's difficulties, the breast cancer diagnostics market has proven its resilience by implementing cutting-edge tactics and technological advancements. To improve diagnostic capabilities and guarantee continuity of care during the pandemic, businesses have hastened the development of digital health platforms, AI-powered diagnostic tools, and remote monitoring devices.

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Global Breast Cancer Diagnostic Market is witnessing significant growth in the near future.

In 2023, the Imaging (Mammography segment accounted for noticeable share of global Breast Cancer Diagnostic Market and is projected to experience significant growth in the near future.

The Screening segment is expected to expand at the significant CAGR retaining position throughout the forecast period.

Some of the key companies Genomic Health , Paragon Biosciences LLC and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.

Frequently Asked Questions (FAQs)